The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

mResvia’s prescribing information indicates that the vaccine was 78.7% effective at preventing RSV that presents with two or more symptoms at 3.7 months of follow-up – a little lower than ...

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

Bayer submits New Drug Application (NDA) for gadoquatrane: The investigational macrocyclic gadolinium-based contrast agent is designed for contrast-enhanced MRI of the central nervous system and other ...